Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Read More

Overview

Feature Articles

Latest Prostate Cancer News and Research

Distinct patient preference profiles identified in prostate cancer care

Distinct patient preference profiles identified in prostate cancer care

AI improves breast cancer staging by analyzing chromatin images

AI improves breast cancer staging by analyzing chromatin images

Study validates Stockholm3 test for prostate cancer in ethnically mixed populations

Study validates Stockholm3 test for prostate cancer in ethnically mixed populations

Stockholm3 blood test proves effective at detecting prostate cancer in different ethnic groups

Stockholm3 blood test proves effective at detecting prostate cancer in different ethnic groups

Research shows the ability of proteins to predict onset of many diverse diseases

Research shows the ability of proteins to predict onset of many diverse diseases

Saffron: A golden remedy for modern health challenges

Saffron: A golden remedy for modern health challenges

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

Diverse genetic data illuminates health disparities across populations

Diverse genetic data illuminates health disparities across populations

Harnessing ctDNA measurements for response assessment in metastatic castration resistant prostate cancer

Harnessing ctDNA measurements for response assessment in metastatic castration resistant prostate cancer

Out-of-pocket costs from diagnostic testing after prostate cancer screening are common and rising

Out-of-pocket costs from diagnostic testing after prostate cancer screening are common and rising

Neighborhood disadvantage linked to higher expression of stress-related genes in prostate tumors

Neighborhood disadvantage linked to higher expression of stress-related genes in prostate tumors

Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer

Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer

Gut bacteria-metabolized equol shows promise in cancer prevention

Gut bacteria-metabolized equol shows promise in cancer prevention

Study highlights hidden aggressiveness in Gleason Grade Group 1 prostate cancer

Study highlights hidden aggressiveness in Gleason Grade Group 1 prostate cancer

What is the difference in risk of early prostate cancer death between men at higher vs lower genetic risk?

What is the difference in risk of early prostate cancer death between men at higher vs lower genetic risk?

Research reveals immune suppression link between cancer and pregnancy

Research reveals immune suppression link between cancer and pregnancy

Machine learning identifies cancer-driving mutations at CTCF binding sites

Machine learning identifies cancer-driving mutations at CTCF binding sites

RNA splicing modulation as a precision approach for neuroendocrine cancer treatment

RNA splicing modulation as a precision approach for neuroendocrine cancer treatment

Pharmacogenomics: A pathway to personalized treatment in prostate cancer

Pharmacogenomics: A pathway to personalized treatment in prostate cancer

Study alerts transwomen to interpret standard prostate cancer screening guidelines with caution

Study alerts transwomen to interpret standard prostate cancer screening guidelines with caution

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.